Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Vey, Norbert  [Clear All Filters]
2024
Saillard C, Cuvelier S, Villaron-Goetgheluck C, Boher J-M, Almeida-Lopez L, Le Corroller A-G, Denis P, Rivieccio C, Calvin S, Vey N, et al. Tripartite prehabilitation of patients with acute myeloid leukaemia and high-risk myelodysplastic syndromes during intensive chemotherapy before allogeneic haematopoietic stem cell transplantation (COHABILIT): protocol for an innovating prospective multic. BMJ Open. 2024;14(3):e076321.
2023
Extermann M, Artz A, Rebollo MAntonio, Klepin HD, Krug U, Loh KPoh, Mims AS, Neuendorff N, Santini V, Stauder R, et al. Treating acute myelogenous leukemia in patients aged 70 and above: Recommendations from the International Society of Geriatric Oncology (SIOG). J Geriatr Oncol. 2023:101626.
2022
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, et al. Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood. 2022.
2021
Bouvier A, Hamel J-F, Delaunay J, Delabesse E, Dumas P-Y, Ledoux MPierre, Peterlin P, Luquet I, Guepin GRoth, Bulabois CEric, et al. Molecular classification and prognosis in younger adults with acute myeloid leukemia patients and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: final results of the GOELAMS/FILO AML 2006-IR trial. Eur J Haematol. 2021.
2020
Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, Fortin G, Meslin P-A, Yakoub-Agha I, Sujobert P, et al. A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.
2018
Ball B, Komrokji RS, Ades L, Sekeres MA, DeZern AE, Pleyer L, Vey N, Almeida A, Germing U, Cluzeau T, et al. Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Adv. 2018;2(16):2063-2071.
2015
Devillier R, Raffoux E, Rey J, Lengline E, Ronchetti A-M, Sebert M, Boissel N, Robin M, Vey N, Kiladjian J-J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2015.
El-Cheikh J, Crocchiolo R, Vai A, Furst S, Bramanti S, Sarina B, Granata A, Faucher C, Mohty B, Harbi S, et al. Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide. Mediterr J Hematol Infect Dis. 2015;7(1):e2015048.
Blaise D, Furst S, Crocchiolo R, El-Cheikh J, Granata A, Harbi S, Bouabdallah R, Devillier R, Bramanti S, Lemarie C, et al. Haploidentical T-cell replete transplantation with post-transplant cyclophosphamide for patients in or above the 6(th) decade of age compared with allogeneic hematopoietic stem cell transplantation from an HLA-matched related or unrelated donor. Biol Blood Marrow Transplant. 2015.
2014
Huguet F, Leguay T, Raffoux E, Rousselot P, Vey N, Pigneux A, Ifrah N, Dombret H. Clofarabine for the treatment of Adult Acute Lymphoid Leukemia A review article by the GRAALL intergroup. Leuk Lymphoma. 2014:1-39.